Libtayo is a fully-human monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein-1), and is claimed to be the first and only treatment specifically
The US Food and Drug Administration (FDA) approved Doptelet on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to
In November 2014, Janssen signed an exclusive worldwide collaboration and license agreement with Geron for the development and commercialization of imetelstat in oncology, including hematologic myeloid malignancies. Janssen
The initial consideration for the sale and transfer of the entire common stock of MTP US is $13.0 million, payable upon Closing, with up to $6m available by
Based in Boston of Massachusetts, Syntimmune is engaged in the development of differentiated drug candidates in a range of autoimmune diseases. As per terms of the deal, Alexion
Gilead’s treatments for chronic hepatitis C virus (HCV) will be launched in the US, through a newly created subsidiary, Asegua Therapeutics. The authorized generics will launch at a
The acquisition of NextWave will allow Tris Pharma to expand its products for the treatment of patients with attention deficit hyperactivity disorder (ADHD). ADHD is a common neurodevelopmental
Sarepta previously announced on July 25, 2018, that the FDA placed the program on clinical hold due to the presence of trace amounts of DNA fragment in research-grade
The interim analysis of the phase III IMpower132 study has demonstrated that Tecentriq and chemotherapy reduced the risk of disease worsening or death (progression-free survival (PFS)) by 40%
In July 2017 Ibex Dedicate, a modular, technology-agnostic biomanufacturing concept, was launched as the first Ibex Solutions offering. Ibex Dedicate offers an innovative facility concept with reduced CAPEX
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.